2021-06-02 06:31:56

HWGB’S JV PARTNER, EBI TO COMPLETE THE 2ND STAGE OF PHASE 4 CLINICAL TRIAL FOR COVID-19 VACCINATION

KUALA LUMPUR, 2 JUNE 2021 – Ho Wah Genting Berhad (“HWGB” or the “Company”) (Bursa Stock Code: 9601), on 14 August 2020 had entered into a joint venture agreement, through its wholly-owned subsidiary HWGB Biotech Sdn Bhd (“HWGB Biotech”), with US-based E-Mo Biology Inc. (EBI) for the research and development of vaccines, immunological treatment and diagnostic product in relation to COVID-19. HWGB had invested US$1 million into EBI for the research and development (“R&D”) of vaccines, immunological treatment, and diagnostic product development in relation to the COVID-19 virus
 
On 28 October 2020, EBI has obtained approval from the United States Food and Drug Administration (“FDA”) to conduct a study titled Phase IV clinical trial. With the approval from the FDA, EBI will be able to conduct the study to evaluate whether an immune response to SARS-CoV-2 RdRp is induced in adults receiving a booster inoculation of IPV and to evaluate the neutralizing activity of antibodies raised to SARS-CoV-2 RdRp.
 
On 25 January 2021, FDA approval was given to EBI for the commencement of the 2nd Stage of the Phase 4 Clinical Trial. EBI is allowed to follow up from the first stage of the study and expand their study into a larger group with an additional 275 subjects in the United States, which will be stratified by age and ethnicity. The expansion of the study will allow EBI to further evaluate and to achieve a more complete characterization of the participants
 
HWGB Biotech’s General Manager (Medical & Pharmaceutical Research), Dr. Yaman Walid Kassab said: “We are delighted with the progress of EBI’s research. We are expecting EBI’s update on the completion of the 2nd Stage of the Phase 4 Clinical Trial and the submission of the report on the 300 participants to FDA”.
  
***

Back